Corporate Banner
Satellite Banner
RNAi
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Recipharm Appoints Prof. Hans Lennernäs to One of its Operating Boards

Published: Tuesday, February 05, 2013
Last Updated: Tuesday, February 05, 2013
Bookmark and Share
Prof. Lennernäs currently manages an IMI project entitled OrBiTo to improve oral drug delivery.

Recipharm Pharmaceutical Development AB has announced the appointment of Dr Hans Lennernäs to the company's Board of Directors.

Dr. Hans Lennernäs is a Professor of Biopharmaceutics at Uppsala University. He currently manages an IMI project entitled OrBiTo, which aims to improve oral drug delivery; controlling a budget of 24.5 MEuro.

His research responsibilities and remit are focused on membrane transport and metabolism of drugs/metabolites in the gastrointestinal tract, hepatobiliary system and cancer tissues.

Dr. Lennernäs has served as the Principal Investigator in an extensive collaboration with the Food Drug & Administration, USA, University of Michigan, USA, and Medical Product Agency, Sweden over the course of several years in which he developed a new guideline for the Biopharmaceutics Classification System.

He has established an extensive and widely used human permeability database.

In addition to his academic achievements, Dr Lennernäs has built an entrepreneurial reputation by cofounding several companies including DuoCort Pharma AB, and LIDDS AB, whilst investing in a number of patents.

“I am very much looking forward to serving on the Board of Directors at Recipharm Pharmaceutical Development AB. Indeed, this is a company with an excellent track record and an impressive long term strategy in place”, Hans Lennernäs commented.

“We are very pleased to welcome a Board Member of Hans Lennernäs calibre”, remarked General Manager Maria Lundberg. “His track record of successfully inventing and developing several novel drug delivery systems that are currently in pre-clinical phase and in preparation for phase I, II and III clinical trials, makes him an excellent addition to the Board. I look forward to Recipharm benefiting from his Board level contribution and insights that will help the company perpetuate its track record of commercial success”.


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,000+ scientific posters on ePosters
  • More than 4,500+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Abstral® Receives Japan’s MHLW Approval
Approval to manufacture highly potent compound for breakthrough pain relief in cancer treatment granted.
Tuesday, September 24, 2013
Scientific News
Scientists Find Evidence That Cancer Can Arise Changes
Researchers at Rockefeller University have found a mutation that affects the proteins that package DNA without changing the DNA itself can cause a rare form of cancer.
Breakthrough Approach to Breast Cancer Treatment
Scripps scientists have designed a drug candidate that decreases growth of breast cancer cells.
A Guide to CRISPR Gene Activation
A comparison of synthetic gene-activating Cas9 proteins can help guide research and development of therapeutic approaches.
Testing Non-Breast/Ovarian Cancer Genes
Researchers have found that expanding gene panel beyond breast/ovarian cancer genes in these patients does not add any clinical benefit. Instead, testing has produced more questions than answers.
Myeloid-Derived Suppressor Cells Play Role in Tumor Growth
Researchers at Baylor College of Medicine have reported a new mechanism that helps cancer cells engage myeloid-derived suppressor cells.
Cancer Cells Coordinate to Form Roving Clusters
Rice University scientists identify ‘smoking gun’ in metastasis of hybrid cells.
Poliovirus Therapy Wins 'Breakthrough' Status
FDA decision will fast-track research on breakthrough Duke brain cancer therapy.
Novel Way to Prevent Deadly Bacterial Infections
Monash scientists may have found a way to stop deadly bacteria from infecting patients. The discovery could lead to a whole new way of treating antibiotic-resistant “superbugs”
New Treatment for Pancreatic Cancer
Researchers at Purdue University have shown how controlling cholesterol metabolism in pancreatic cancer cells reduces metastasis.
Big Data Can Save Lives
The sharing of genetic information from millions of cancer patients around the world could be key to revolutionising cancer prevention and care, according to a leading cancer expert from Queen's University Belfast.
SELECTBIO

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,000+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,500+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!